CATALOGO DEI PRODOTTI DELLA RICERCA

SIMBOLO, Michele
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 5.293
NA - Nord America 5.070
AS - Asia 3.743
SA - Sud America 489
AF - Africa 128
OC - Oceania 15
Continente sconosciuto - Info sul continente non disponibili 3
Totale 14.741
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.933
RU - Federazione Russa 2.154
SG - Singapore 1.293
CN - Cina 1.251
GB - Regno Unito 868
IT - Italia 751
BR - Brasile 376
HK - Hong Kong 353
DE - Germania 337
VN - Vietnam 309
SE - Svezia 283
IE - Irlanda 239
FR - Francia 220
FI - Finlandia 138
KR - Corea 123
BD - Bangladesh 79
CA - Canada 78
NL - Olanda 65
IN - India 60
JP - Giappone 50
UA - Ucraina 45
ID - Indonesia 37
AR - Argentina 36
MX - Messico 35
ES - Italia 33
TR - Turchia 33
PL - Polonia 31
AT - Austria 30
BE - Belgio 29
IQ - Iraq 29
NG - Nigeria 29
EC - Ecuador 21
BJ - Benin 18
CO - Colombia 17
PK - Pakistan 16
SA - Arabia Saudita 16
TG - Togo 16
ZA - Sudafrica 16
AU - Australia 14
MA - Marocco 14
UZ - Uzbekistan 12
VE - Venezuela 11
IR - Iran 10
CL - Cile 9
NP - Nepal 9
JO - Giordania 8
PH - Filippine 8
LT - Lituania 7
TN - Tunisia 7
UY - Uruguay 7
CH - Svizzera 6
EG - Egitto 6
KG - Kirghizistan 6
LV - Lettonia 6
MY - Malesia 6
AL - Albania 5
CZ - Repubblica Ceca 5
IL - Israele 5
PE - Perù 5
SK - Slovacchia (Repubblica Slovacca) 5
TW - Taiwan 5
CR - Costa Rica 4
ET - Etiopia 4
KE - Kenya 4
NI - Nicaragua 4
PT - Portogallo 4
PY - Paraguay 4
AE - Emirati Arabi Uniti 3
AZ - Azerbaigian 3
BG - Bulgaria 3
EE - Estonia 3
GA - Gabon 3
GR - Grecia 3
HR - Croazia 3
MT - Malta 3
PA - Panama 3
RS - Serbia 3
TT - Trinidad e Tobago 3
BB - Barbados 2
BO - Bolivia 2
CY - Cipro 2
DK - Danimarca 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
EU - Europa 2
GE - Georgia 2
HU - Ungheria 2
JM - Giamaica 2
KW - Kuwait 2
LK - Sri Lanka 2
MD - Moldavia 2
NO - Norvegia 2
PS - Palestinian Territory 2
RO - Romania 2
SN - Senegal 2
SY - Repubblica araba siriana 2
TH - Thailandia 2
BA - Bosnia-Erzegovina 1
BQ - ???statistics.table.value.countryCode.BQ??? 1
BS - Bahamas 1
Totale 14.721
Salva come PNG Salva come JPEG
Città #
Moscow 742
Southend 698
Singapore 677
Ashburn 631
San Jose 510
Chandler 507
Dallas 487
Hong Kong 342
Verona 336
Beijing 252
Dublin 235
New York 173
Ann Arbor 146
Woodbridge 144
Jacksonville 137
The Dalles 131
Council Bluffs 128
Munich 122
Los Angeles 114
Ho Chi Minh City 99
Jinan 86
Redmond 78
Lawrence 72
Princeton 72
Wilmington 68
Hanoi 66
Shenyang 63
Helsinki 55
Nanjing 53
Houston 51
London 51
São Paulo 49
Redondo Beach 46
Tianjin 46
Columbus 45
Orem 45
Buffalo 43
Santa Clara 43
Tokyo 42
Zhengzhou 41
Milan 39
Frankfurt am Main 34
Bologna 33
Hebei 33
Turku 33
Montreal 31
Brussels 29
Haikou 29
Abuja 28
Ningbo 28
Sindelfingen 28
Warsaw 28
Changsha 27
Hangzhou 27
Nanchang 26
Seoul 26
Guangzhou 25
Nuremberg 24
Brooklyn 22
Amsterdam 21
Poplar 21
Seattle 21
Taizhou 21
Vienna 21
Denver 20
Dearborn 19
Jakarta 19
Kent 19
Mexico City 19
Cotonou 18
Taiyuan 18
Toronto 18
Chicago 17
Rome 17
San Francisco 17
Falls Church 16
Jiaxing 16
Lomé 16
Shanghai 16
Haiphong 15
Phoenix 15
Rio de Janeiro 15
Atlanta 14
Boston 14
Dong Ket 14
Redwood City 14
Stockholm 14
Chennai 13
Da Nang 13
Falkenstein 13
Baghdad 12
Belo Horizonte 12
Johannesburg 12
Norwalk 12
Paris 12
Barnet 11
Lappeenranta 11
Piscataway 11
Washington 11
City of London 10
Totale 8.914
Salva come PNG Salva come JPEG
Nome #
MAP Kinase inhibition reshapes tumour microenvironment of mouse pancreatic cancer by depleting anti-inflammatory macrophages 303
DNA Qualification Workflow for Next Generation Sequencing of Histopathological Samples 283
Whole-genome landscape of pancreatic neuroendocrine tumours 281
Comprehensive molecular portrait using next generation sequencing of resected intestinal-type gastric cancer patients dichotomized according to prognosis 254
Ampulla of Vater Carcinoma: Sequencing Analysis Identifies TP53 Status as a Novel Independent Prognostic Factor and Potentially Actionable ERBB, PI3K, and WNT Pathways Gene Mutations 248
BRCA somatic and germline mutation detection in paraffin embedded ovarian cancers by next-generation sequencing 239
Diffuse gliomas in patients aged 55 years or over: A suggestion for IDH mutation testing 230
A cross-species analysis in pancreatic neuroendocrine tumors reveals molecular subtypes with distinctive clinical, metastatic, developmental, and metabolic characteristics 228
High-throughput mutation profiling identifies novel molecular dysregulation in high-grade intraepithelial neoplasia and early gastric cancers 226
Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups 219
High-throughput mutation profiling improves diagnostic stratification of sporadic medullary thyroid carcinomas. 209
Immunoevolution of mouse pancreatic organoid isografts from preinvasive to metastatic disease 209
IDH-wild type glioblastomas featuring at least 30% giant cells are characterized by frequent RB1 and NF1 alterations and hypermutation 206
Centrosome Linker-induced Tetraploid Segregation Errors Link Rhabdoid Phenotypes and Lethal Colorectal Cancers 205
Corrigendum: Whole-genome landscape of pancreatic neuroendocrine tumours 203
Comparison Between Prognostic Classifications in De Novo Metastatic Hormone Sensitive Prostate Cancer 203
Extrahepatic Distal Cholangiocarcinoma vs. Pancreatic Ductal Adenocarcinoma: Histology and Molecular Profiling for Differential Diagnosis and Treatment 200
Cholangiocarcinoma Heterogeneity Revealed by Multigene Mutational Profiling: Clinical and Prognostic Relevance in Surgically Resected Patients 197
Reporting tumor molecular heterogeneity in histopathological diagnosis 190
Perihilar and distal extrahepatic cholangiocarcinomas show different genetic profiles but share MYC copy gain and TP53 mutation as independent poor prognostic markers 188
H3K27me3 immunostaining is diagnostic and prognostic in diffuse gliomas with oligodendroglial or mixed oligoastrocytic morphology 186
Clinical and Genomic Characterization of Pancreatic Ductal Adenocarcinoma with Signet-Ring/Poorly Cohesive Cells 185
Genetic alterations analysis in prognostic stratified groups identified TP53 and ARID1A as poor clinical performance markers in intrahepatic cholangiocarcinoma 185
Comparative Lesions Analysis Through a Targeted Sequencing Approach 185
Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas 182
Preliminary results of PRINCiPe (predictors of resistance to immunotherapy with nivolumab [NIV]) study in advanced pretreated non-small cell lung cancer (APNSCLC), investigating the role of an immune genomic signature (IGS) including JAK2, JAK3, PIAS4, PTPN2, STAT3, IFNAR2 alterations 177
Gene expression profiling of lung atypical carcinoids and large cell neuroendocrine carcinomas identifies three transcriptomic subtypes with specific genomic alterations 177
Next-generation sequencing for genetic testing of familial colorectal cancer syndromes 174
Molecular alterations associated with metastases of solid pseudopapillary neoplasms of the pancreas 173
Lung neuroendocrine tumours: deep sequencing of the four WHO histotypes reveals chromatin remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D 171
Carbon dating cancer: defining the chronology of metastatic progression in colorectal cancer 168
FrequentNRG1fusions in Caucasian pulmonary mucinous adenocarcinoma predicted by Phospho-ErbB3 expression 168
ERG alterations and mTOR pathway activation in primary prostate carcinomas developing castration-resistance 167
Perineural Invasion is a Strong Prognostic Moderator in Ampulla of Vater Carcinoma: A Meta-analysis 162
Exosomal miRNA signatures of pancreatic lesions 161
Anticipating EGFR Targeting in Early Stages of Lung Cancer: Leave No Stone Unturned 161
Integrative characterization of intraductal tubulopapillary neoplasm (ITPN) of the pancreas and associated invasive adenocarcinoma 160
Poorly Cohesive Gastric Cancers Showing the Transcriptomic Hallmarks of Epithelial-Mesenchymal Transition Behave Aggressively 159
Next-Generation Histopathologic Diagnosis: A Lesson From a Hepatic Carcinosarcoma 157
ARID1A mutational status in non-small cell lung cancer: from molecular pathology to clinical implications with a focus on the relationships with EGFR 155
Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort 155
PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer 155
Genomic characterization of biliary tract cancers identifies driver genes and predisposing mutations 154
Juvenile polyposis diagnosed with an integrated histological, immunohistochemical and molecular approach identifying new SMAD4 pathogenic variants 153
Glioblastoma with tumor-to-tumor metastasis from lung adenocarcinoma 151
Potential role of RICTOR copy number gain (CNG) as a key biomarker of mTOR activity: A comprehensive preclinical analysis in squamous cell lung cancer (SQLC) models 150
Pro-inflammatory factors secreted by pancreatic cancers with evasive resistance to anti-VEGF treatment contribute to malignant progression by inducing EMT 150
Genomic characterization of undifferentiated sarcomatoid carcinoma of the pancreas 149
Long-term organoid culture of a small intestinal neuroendocrine tumor 147
Collapse of the Plasmacytoid Dendritic Cells compartment in advanced cutaneous melanomas by components of the tumor cell secretome 147
Molecular characterization of extrahepatic cholangiocarcinoma: perihilar and distal tumours display divergent genomic and transcriptomic profiles 146
Mucinous cystic neoplasms and simple mucinous cysts are two distinct precursors of pancreatic cancer: clinicopathological, genomic, and transcriptomic characterization 145
Complete remission with sunitinib in a poor-risk patient with metastatic renal cell carcinoma: the fine balance between toxicity and efficacy 143
Combined Large Cell Neuroendocrine Carcinomas of the Lung: Integrative Molecular Analysis Identifies Subtypes with Potential Therapeutic Implications 141
Molecular Profiling of 22 Primary Atypical Meningiomas Shows the Prognostic Significance of 18q Heterozygous Loss and CDKN2A/B Homozygous Deletion on Recurrence-Free Survival 137
Techniques and New Diagnostic Technologies (Limitations, Applications) 135
An Insight on Functioning Pancreatic Neuroendocrine Neoplasms 133
Intraventricular Meningiomas: Clinical-Pathological and Genetic Features of a Monocentric Series 133
Targeted next-generation sequencing identifies genomic abnormalities potentially driving the prognosis of early-stage invasive lobular breast carcinoma patients stratified according to a validated clinico-pathological model 131
Undifferentiated Sarcomatoid Carcinoma of the Pancreas: From Histology and Molecular Pathology to Precision Oncology 131
Molecular and Clinical Insights in Malignant Brenner Tumor of the Testis With Liver Metastases:A Case Report 129
pRB immunostaining in the differential diagnosis between pleomorphic xanthoastrocytoma and glioblastoma with giant cells 126
Ultra-Mutation in IDH Wild-Type Glioblastomas of Patients Younger than 55 Years is Associated with Defective Mismatch Repair, Microsatellite Instability, and Giant Cell Enrichment 126
Clinical-Pathological, Immunohistochemical, and Genetic Characterization of a Series of Posterior Pituitary Tumors 123
An Overview of Circulating Biomarkers in Neuroendocrine Neoplasms: A Clinical Guide 122
MULTIGENE MUTATIONAL PROFILING OF CHOLANGIOCARCINOMAS IDENTIFIES ACTIONABLE MOLECULAR SUBGROUPS 122
Atypical meningiomas with an immunohistochemical profile consistent with hypermetabolic or proliferative molecular groups show high mitotic index, chromosomal instability, and higher recurrence risk 119
Unmasking the impact of Rictor in cancer: novel insights of mTORC2 complex 119
Il profilo molecolare 118
Multigene mutational profiling of biliary tract cancer is related to the pattern of recurrence in surgically resected patients 118
Integrative molecular analysis of combined small-cell lung carcinomas identifies major subtypes with different therapeutic opportunities 117
Characterization of two transcriptomic subtypes of marker-null large cell carcinoma of the lung suggests different origin and potential new therapeutic perspectives 116
Glucagon-Producing Pancreatic Neuroendocrine Tumors (Glucagonomas) are Enriched in Aggressive Neoplasms with ARX and PDX1 Co-expression, DAXX/ATRX Mutations, and ALT (Alternative Lengthening of Telomeres) 114
Tissue- and liquid-biopsy based NGS profiling in advanced non-small-cell lung cancer in a real-world setting: the IMMINENT study 113
Ascl1 and OTP tumor expressions are associated with Disease-Free Survival in Lung Atypical Carcinoids 111
MIR21 drives resistance to Heat Shock Protein 90 inhibition in cholangiocarcinoma 110
Large Cell Neuro-Endocrine Carcinoma of the Lung: Current Treatment Options and Potential Future Opportunities 110
Tubulocystic Carcinoma of Bile Ducts: A Distinct Type of Cholangiocarcinoma Associated With Adenofibroma-type Lesions 107
New genomic landscapes and therapeutic targets for biliary tract cancers 107
Exceptional Response in BRAF p.V600E-Mutant Enteric-Type Adenocarcinoma of the Lung With Cutaneous Spread: A Case Report 107
Metformin enhances cisplatin-induced apoptosis and prevents resistance to cisplatin in co-mutated KRAS/LKB1 Non-Small Cell Lung Cancer (NSCLC) 106
Transcriptome analysis of primary sporadic neuroendocrine tumours of the intestine identified three different molecular subgroups 105
Evaluation of Correlations between Genetic Variants and High-Resolution Computed Tomography Patterns in Idiopathic Pulmonary Fibrosis 104
Identification of Targetable Liabilities in the Dynamic Metabolic Profile of EGFR-Mutant Lung Adenocarcinoma: Thinking beyond Genomics for Overcoming EGFR TKI Resistance 99
Pembrolizumab Activity in Recurrent High-Grade Gliomas with Partial or Complete Loss of Mismatch Repair Protein Expression: A Monocentric, Observational and Prospective Pilot Study 98
Patterns of gene mutations in bile duct cancers: is it time to overcome the anatomical classification? 96
Mutational and copy number asset of primary sporadic neuroendocrine tumors of the small intestine 95
Most high-grade neuroendocrine tumours of the lung are likely to secondarily develop from pre-existing carcinoids: innovative findings skipping the current pathogenesis paradigm 94
Pathology of Biliary Tract Cancers 94
Prognostic and predictive implications of tumor suppressor gene alterations in non-small cell lung cancer 91
Myeloid and T-Cell Microenvironment Immune Features Identify Two Prognostic Sub-Groups in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms 89
Gene Expression Profiling of Pancreas Neuroendocrine Tumors with Different Ki67-Based Grades 84
Combined adenocarcinoma–atypical carcinoid of the lung. Targeted Next-Generation Sequencing (NGS) suggests a monoclonal origin of the two components 79
Comprehensive genomic and transcriptomic characterization of high-grade gastro-entero-pancreatic neoplasms 76
Hepatocellular Carcinoma Genetic Landscape 76
Exploring the molecular and biological background of lung neuroendocrine tumours 76
Metastasis of lung carcinoid in the thyroid gland after 18 years: it is never too late. A case report and review of the literature 76
Loss of Primary Cilia Potentiates BRAF/MAPK Pathway Activation in Rhabdoid Colorectal Carcinoma: A Series of 21 Cases Showing Ciliary Rootlet CoiledCoil (CROCC) Alterations 74
Lung carcinoid tumours: histology and Ki-67, the eternal rivalry 64
Oncocytic and spindle cell typical carcinoids of lung: different immunophenotype and biological behavior 46
Totale 14.876
Salva come PNG Salva come JPEG
Categoria #
all - tutte 52.847
article - articoli 47.986
book - libri 0
conference - conferenze 2.227
curatela - curatele 0
other - altro 1.336
patent - brevetti 0
selected - selezionate 0
volume - volumi 1.298
Totale 105.694
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202155 0 0 0 0 0 0 0 0 0 0 0 55
2021/2022824 77 227 44 70 44 18 36 51 37 17 58 145
2022/20231.484 88 172 112 256 127 351 16 84 198 17 34 29
2023/2024867 40 59 82 91 109 154 49 63 12 53 131 24
2024/20252.250 115 119 123 383 79 89 117 87 310 146 229 453
2025/20267.211 503 332 509 1.209 1.895 431 616 389 561 450 156 160
Totale 14.969